Vontobel Holding Ltd. Sells 247,874 Shares of Annexon, Inc. (NASDAQ:ANNX)

Vontobel Holding Ltd. trimmed its holdings in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 27.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 650,911 shares of the company's stock after selling 247,874 shares during the quarter. Vontobel Holding Ltd. owned about 1.22% of Annexon worth $2,955,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ANNX. Quantbot Technologies LP lifted its stake in shares of Annexon by 630.8% in the first quarter. Quantbot Technologies LP now owns 9,500 shares of the company's stock worth $25,000 after buying an additional 8,200 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Annexon by 31.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,992 shares of the company's stock worth $31,000 after acquiring an additional 1,903 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Annexon during the 1st quarter worth $41,000. Hsbc Holdings PLC bought a new stake in Annexon during the third quarter valued at about $45,000. Finally, Jane Street Group LLC acquired a new stake in shares of Annexon in the first quarter valued at about $46,000.

Annexon Price Performance

Shares of ANNX traded up $0.12 on Friday, reaching $4.56. 1,154,136 shares of the stock traded hands, compared to its average volume of 1,508,966. The firm has a market cap of $410.54 million, a price-to-earnings ratio of -2.56 and a beta of 1.14. Annexon, Inc. has a 12 month low of $1.57 and a 12 month high of $8.40. The stock's 50-day moving average price is $5.75 and its 200-day moving average price is $4.05.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. As a group, equities research analysts forecast that Annexon, Inc. will post -1.36 earnings per share for the current fiscal year.

Insider Activity at Annexon

In other news, CEO Douglas Love sold 5,782 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $5.54, for a total value of $32,032.28. Following the completion of the transaction, the chief executive officer now directly owns 196,121 shares of the company's stock, valued at approximately $1,086,510.34. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 8,940 shares of company stock valued at $49,514 over the last quarter. 19.11% of the stock is owned by company insiders.

Analyst Ratings Changes

ANNX has been the subject of several research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Annexon in a research report on Thursday, April 11th. Wells Fargo & Company upped their price target on Annexon from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Wednesday, March 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Annexon in a research report on Wednesday, April 3rd. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Annexon in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. upped their target price on shares of Annexon from $11.00 to $13.00 and gave the company an "overweight" rating in a research note on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $14.43.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.